Compare equities side by side
Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
Haemonetics is a specialized medical technology company focused on blood and plasma management solutions, operating two primary segments: Plasma (collection devices and disposables for plasma centers) and Hospital (blood management systems for surgical and transfusion applications). The company derives approximately 60% of revenue from recurring disposables tied to installed equipment base, creating predictable cash flows. Stock performance is driven by plasma center utilization rates, hospital procedure volumes, and new product adoption in surgical blood management.
Haemonetics operates a classic razor-razorback model: place capital equipment (plasma collection devices, cell savers) at customer sites, then generate recurring revenue from proprietary disposables required for each procedure. Plasma disposables carry 60-65% gross margins with multi-year supply contracts. Hospital segment margins are lower (50-55%) but benefit from switching costs once integrated into surgical workflows. Pricing power derives from FDA regulatory barriers, installed base lock-in, and limited competition (Fresenius Kabi in plasma, LivaNova in cell salvage). The company targets 200-300 basis points of annual operating margin expansion through manufacturing automation and portfolio optimization.
Plasma center utilization rates and donor traffic trends - directly impacts disposables volume which represents 45-50% of total revenue
Hospital surgical procedure volumes, particularly cardiac and orthopedic surgeries where Cell Saver adoption is highest
New product launch momentum: Vascular Closure Device (VCD) rollout, NexSys PCS upgrades, TEG Manager software adoption
Plasma pricing dynamics and customer inventory destocking cycles at major customers (CSL, Grifols, Takeda)
Margin expansion trajectory driven by manufacturing efficiency and mix shift toward higher-margin hospital products
Plasma industry consolidation risk - top 3 customers (CSL, Grifols, Takeda) represent 40-45% of revenue; customer bankruptcies or vertical integration into device manufacturing could disrupt revenue streams
Regulatory pathway changes - FDA 510(k) process modifications or increased scrutiny on blood safety could delay new product launches or require costly clinical trials; EU MDR implementation added 12-18 month approval timelines
Reimbursement pressure - CMS payment rate cuts for hospital blood management procedures could reduce capital equipment budgets; plasma reimbursement changes in Europe affect customer profitability
Fresenius Kabi expanding plasma collection device footprint in Europe and Asia-Pacific, potentially displacing Haemonetics in key growth markets
Technology disruption from pathogen reduction systems (Cerus, Terumo BCT) potentially reducing need for traditional blood management in certain applications
Private equity-backed competitors (Instrumentation Laboratory in hemostasis) investing aggressively in sales force expansion and product development
Debt maturity profile - $375M net debt with portions maturing 2027-2029 requiring refinancing in potentially higher rate environment
Working capital volatility - customer inventory destocking cycles can create 200-300 bps revenue growth swings quarter-to-quarter, pressuring cash conversion
Pension and post-retirement obligations estimated at $40-50M unfunded, though not material relative to $2.8B market cap
moderate - Plasma segment exhibits counter-cyclical characteristics as donor traffic increases during economic weakness (unemployment drives plasma donations). Hospital segment is moderately pro-cyclical, tied to elective surgical volumes which decline in recessions but are less discretionary than cosmetic procedures. Overall company revenue showed resilience during 2020 downturn with only 3% decline, recovering to growth by 2021. Healthcare capital equipment spending by hospitals correlates with patient volumes and reimbursement rates.
Rising rates create modest headwinds through two channels: (1) Higher cost of debt refinancing - company carries $375M net debt (1.34x equity) with portions subject to floating rates, adding 50-75 bps interest expense per 100 bps rate increase; (2) Valuation multiple compression as medtech stocks typically trade at premium P/E ratios (20-25x) which contract when risk-free rates rise. However, business fundamentals are largely rate-insensitive as hospitals finance equipment through operating budgets rather than credit-dependent purchases. Limited direct impact on end-market demand.
Minimal direct credit exposure. Customer base is dominated by investment-grade rated plasma companies (CSL, Takeda) and hospital systems with stable cash flows. Receivables risk is low. Company's own credit profile is investment-grade equivalent (estimated BB+/BBB-) with 1.3x net debt/EBITDA, manageable given 5% FCF yield and deleveraging trajectory. No material exposure to consumer credit conditions or commercial lending cycles.
value - Stock trades at 9.9x EV/EBITDA vs medtech peer average of 14-16x, offering 30-40% valuation discount despite 20%+ ROE and improving margins. Recent 18.5% pullback (3-month) creates entry point for investors betting on margin expansion story and plasma market recovery. Attracts healthcare specialists focused on recurring revenue models and operational turnarounds. Limited dividend (estimated <1% yield) reduces income investor appeal. 42.7% EPS growth demonstrates emerging growth characteristics, but modest 4% revenue growth keeps momentum investors away.
moderate - Estimated beta of 0.9-1.1 based on healthcare equipment peer group. Stock exhibits 20-30% intra-year drawdowns during customer destocking cycles or surgical volume disruptions (COVID-19 saw 35% peak-to-trough decline). Quarterly earnings volatility driven by lumpy capital equipment orders and plasma customer inventory management. Lower volatility than small-cap biotech but higher than diversified healthcare conglomerates. Options market typically prices 25-35% implied volatility.